Synthetic Cannabinoids - Symptoms of Poisoning and Law

In an observation of 44 emergency room patients, generalized seizures occurred in 27 percent, and central nervous system depression in 61 percent. In Poland, this entire group is banned in two independent ways: named molecules are listed mainly in psychotropic substance schedules, and the rest are covered by molecular structure description in the new psychoactive substances list. This text describes a group of illegal substances that kill and is not a usage guide. We write it for parents, teachers, rescuers, and everyone who wants to understand why “herbal designer drug” has nothing to do with cannabis except appearance. Here you will find pharmacology, poisoning symptoms, legal status, emergency procedures, and separation of two groups that are frequently confused in the media. Every number in the text comes from a study that can be opened and read. Where a popular claim had no such support, we removed it and wrote plainly that there is no evidence instead of replacing it with a more cautious formulation of the same content.

KEY INFORMATION
• Synthetic cannabinoids bind the CB1 receptor more strongly than THC, and their action in studies was described as 2 to 100 times stronger (Castaneto 2014).
• Among 44 emergency room patients after newer compounds of this group, generalized seizures occurred in 27%, and central nervous system depression in 61% (Hermanns-Clausen 2018).
• In Poland, named compounds of this group are mainly listed in psychotropic substances group II-P, some among narcotics and new psychoactive substances, and the structural definition also covers unnamed derivatives.
• Standard marijuana tests do not detect them; dedicated toxicological analysis is needed.
• In case of suspected poisoning, call 112 and secure the packaging.

What are synthetic cannabinoids and where did they come from?

These are laboratory-made compounds that bind to cannabinoid receptors CB1 and CB2. They are not cannabis extracts and contain neither THC, cannabidiol, nor plant terpenes. They were created as research tools and entered illegal circulation after chemical descriptions were published.

The method of producing street products is primitive. Pure substance is dissolved in an organic solvent, sprayed onto dried herbs, and after evaporation, something resembling marijuana is formed. This is described by both pharmacological reviews and reports from sanitary services investigating poisoning outbreaks (Castaneto 2014). Newer products are also added to vaporizer cartridges, as noted by the American National Institute on Drug Abuse (NIDA).

The first market wave was based on JWH series compounds, developed in the 1990s for endocannabinoid system research. They were never intended for human consumption. Around 2008, they appeared in herbal blends sold as “legal highs”, largely because they evaded standard cannabinoid tests.

Since then, chemical structures have been constantly changing. A literature review describes this as a steady stream of new compounds produced in illegal labs to circumvent current schedules. The pace can be high: in 2014 alone, the European Monitoring Centre for Drugs reported thirty new synthetic cannabinoids (Hermanns-Clausen 2018). For users, this means one thing: the name on the package tells nothing about the content.

It is worth knowing why these molecules were created at all, as it explains their potency. They were designed as probes to study the endocannabinoid system or as starting points for drugs, and in such applications, compounds that bind the receptor as strongly and selectively as possible are sought. A desirable feature in a test tube becomes a hazard when the same molecule is smoked without any dose control.

Trade names change as quickly as chemistry. The same content is often sold under several names simultaneously, and the label stating the product is not intended for human consumption serves only as a legal shield. Treating it as composition information is a mistake.

Why are “Spice” and “Mocarz” more dangerous than marijuana?

The reason is pharmacological. THC only partially stimulates the CB1 receptor and thus has a natural ceiling effect. Synthetic compounds fully stimulate the same receptor with very high potency. Studies on indole and indazole derivatives showed EC50 values at the CB1 receptor between 0.24 and 21 nanomolar (Banister 2015).

A comprehensive review puts it more cautiously and gives a range: most compounds detected in herbal products bind the CB1 receptor more strongly than THC, and their action in lab and animal studies was 2 to 100 times stronger. The popular figure “100 to 800 times” describes only a single research compound from the HU series and does not apply to the whole group. We removed it from this text because it was misleading here.

The second difference concerns what the product lacks. In the plant, alongside THC, cannabidiol is present, which in cell studies weakens the CB1 receptor response to agonists (Laprairie 2015). In herbal blends with synthetics, there is nothing fulfilling this role. What remains is pure, unshielded receptor stimulation.

The third difference is practical. Effects described after these compounds include symptoms absent after marijuana, such as acute kidney failure, seizures, and respiratory disorders. Literature notes that long-term consequences remain unknown because no long-term observations have been conducted.

That the effect is indeed via the CB1 receptor was shown in animals. Administration of AB-FUBINACA and AB-PINACA to rats at doses from 0.3 to 3 milligrams per kilogram caused dose-dependent body temperature drop and heart rate slowing, and prior administration of a CB1 receptor blocker abolished the temperature drop. Blocking the CB2 receptor did not. This is proof of mechanism, not just correlation.

The dose scale in this experiment also says something important. The effect appeared at fractions of a milligram per kilogram of body weight, i.e., amounts that cannot be measured at home. With the substance sprayed on herbs, the user has no reference point to start cautiously.

Which chemical groups appear most often in products?

There are a dozen or so chemical families that replace each other every few years. The table below organizes those that have actually appeared in European seizures and poisoning reports. Group names are important because they help understand why banning one molecule does not end the matter.

Comparison of third-generation poisonings with earlier ones was unequivocal. Neuropsychiatric symptoms were more frequent, the course more severe, and duration longer than with JWH series compounds. Authors note the observation included 44 patients and requires confirmation on a larger group. Differences between natural and synthetic cannabinoids are summarized separately in a comparison of phytocannabinoids, endocannabinoids, and synthetics.

The Polish thread has a name and date. MDMB-CHMICA appeared on the European market in September 2014, and in Poland it was detected in an herbal blend sold as “Mocarz”, which in early July 2015 caused a large poisoning outbreak. This was described in toxicological literature by an analyst investigating one of the deaths from that period (Adamowicz 2016).

Names in the table should be treated as a snapshot of the market, not a closed list. Producers abandon a compound when it is scheduled and release the next with a modified side chain. Therefore, identifying a substance by packaging is impossible even for a laboratory until analysis is performed.

What symptoms does synthetic cannabinoid poisoning cause?

The clinical picture differs from marijuana poisoning and can be violent. The best available data come from a prospective observation of 44 emergency room patients with analytically confirmed presence of AB-CHMINACA or MDMB-CHMICA. Poisoning was assessed as mild in four persons, moderate in thirty-one, and severe in nine (Hermanns-Clausen 2018).

A Swedish series of nine analytically confirmed MDMB-CHMICA poisonings showed a similar picture: eight cases were moderate or severe, five required intensive care, and seizures and deep unconsciousness were common. All survived. Authors note that except for one case, other substances were also detected, complicating symptom attribution to a single molecule (Bäckberg 2017).

Outside the nervous system, nausea and vomiting, shallow breathing, increased blood pressure, accelerated heart rate, chest pain, muscle tremors, and acute kidney failure were described. The latter was subject to a separate epidemiological investigation: sixteen cases of acute kidney injury in six US states were linked to use of such products, with XLR-11 detected in some samples (CDC report 2013). Investigators noted that no single brand or molecule explained all sixteen cases.

Attributing symptoms to one substance is difficult in this group due to a recurring reason. In the emergency room study, nineteen of forty-four cases involved more than one synthetic cannabinoid, and seven had additional psychoactive substances detected. The product is often a mixture of several compounds in unknown proportions.

The literature also adds suicidal thoughts and cognitive dysfunctions to the symptom list. It separately emphasizes that nothing is known about long-term consequences because no long-term observations have been conducted. Lack of data is not good news but a gap.

Why can’t synthetic doses be controlled?

Because the product is not a mixture but herbs sprayed with a solution. After solvent evaporation, molecules settle unevenly, and the user cannot check how much substance is in their portion. Also, very small amounts are needed to cause effects, so a slight difference in distribution means a large dose difference.

The concentration scale is shown by analysis of a product from a mass poisoning in New York. On July 12, 2016, thirty-three people were poisoned in one district, and the product named “AK-47 24 Karat Gold” contained AMB-FUBINACA at 16.0 milligrams per gram with a standard deviation of 3.9 (Adams 2017). Authors classified this compound as ultrastrong.

Honesty about knowledge limits is required here. There is a claim that “hot spots” in one package can have concentrations 10 to 50 times higher than average. We found no publication measuring such multiples, so we removed this number instead of repeating it. Uneven distribution is documented and sufficient as a warning, but no specific multiplier was given.

The practical conclusion remains the same regardless of numbers. There is no way to dose the product cautiously when active substance content is randomly distributed, and trying “a small amount” does not protect because the next portion from the same package may be completely different. User experience is no safeguard here.

The order of magnitude is shown by comparing two numbers. The product contained concentrations on the order of milligrams per gram of herb, while in a described death, the substance concentration in blood taken ante-mortem was 5.6 nanograms per milliliter. Between what is held in hand and what decides life lies six orders of magnitude. At such a range, a pinch of herb mistake ceases to be a small mistake.

Are synthetic cannabinoids addictive?

Withdrawal syndrome descriptions exist, but the evidence base is thin and must be said plainly. A 2025 systematic review searched four literature databases and found eleven case reports meeting inclusion criteria (Sharma and Weinstein 2025). This is case material, not a cohort study.

In these eleven reports, psychosis, agitation with irritability, nausea and vomiting, seizures, accelerated heart rate, and insomnia were most often noted. Symptoms appeared within 24 to 48 hours in two-thirds of cases and usually resolved within a week. Single cases of delirium and rhabdomyolysis were also described.

Authors cautiously conclude: withdrawal symptoms can be more severe and less predictable than with natural cannabinoids, especially in daily users, and the syndrome remains poorly studied. Quality of reports was variable, averaging eight out of thirteen checklist items.

For families, this means a practical matter. Stopping use may not be mild and can require medical help, not just psychological support. If seizures or psychotic symptoms appear after cessation, it is a medical situation, not home observation.

Most described cases involved men, with an average age just over twenty-eight years. The group is too small to draw prevalence conclusions, and authors treat it as such. It shows who wards see in practice: young adults hospitalized not for use but for cessation.

A separate difficulty is that no proven treatment scheme exists for this syndrome. The review ends with a call for further mechanism research and evidence-based treatment development. In practice, this means symptomatic treatment and case-by-case decisions.

What is the legal status of synthetic cannabinoids in Poland?

They are illegal and subject to criminal law in two ways simultaneously. Named compounds are listed by name: JWH-018 (item 59), AM-2201 (item 60), MDMB-CHMICA (item 48), AB-CHMINACA (item 45), AB-FUBINACA (item 64), XLR-11 (item 50), 5F-MDMB-PINACA (item 51), and 4F-MDMB-BINACA (item 67) are in the psychotropic substances group II-P list, and HU-210 (item 79) in narcotics group I-N (Minister of Health regulation, consolidated text Dz.U. 2024 pos. 1139). Some synthetics, like 5F-AB-PINACA, are named in the new psychoactive substances list.

The second mechanism is more general and closes the gap. The annex with the new psychoactive substances list contains a point titled “Synthetic cannabinoids (cannabinoid mimetics) - group III-NPS”, which defines banned compounds by molecular structure description, not by name. This way, a slight structural modification does not exclude a new derivative from the ban. Since May 22, 2025, the definition is broader with additional structural variants (Dz.U. 2025 pos. 598). The basis for extending responsibility to these substances was the Act of July 20, 2018 (Dz.U. 2018 pos. 1490), effective August 21, 2018.

All cited provisions come from the Act on Counteracting Drug Addiction, consolidated text Dz.U. 2023 pos. 1939. The distinction between art. 62 and art. 62b is practically important because the qualification depends on which list the molecule is in. For the buyer, however, it is irrelevant: neither path means legality.

What to do if synthetic drug poisoning is suspected?

Call 112 and do not wait for symptoms to develop. Seizures, loss of consciousness, chest pain, cyanosis, breathing disorders, extreme agitation with aggression, or loss of reality contact are situations where response time matters. Secure the substance packaging because without it, identification in hospital is often impossible.

Before ambulance arrival, do little and do it calmly. Speak softly to the person, do not shout, do not induce vomiting, do not give food or drink. Place an unconscious person who is breathing in the recovery position and monitor breathing. If breathing stops, start resuscitation and continue until help arrives.

There is a claim that quick intervention reduces mortality from 4.3% to below 1%. We found no study providing these figures and removed them from this text. What can be said honestly is different: a death after single use was described where loss of consciousness and cardiac arrest occurred within minutes of ignition, and the patient died after four days of hospitalization due to multiple organ failure (Adamowicz 2016). At such a pace, every minute counts against survival.

Numbers worth saving: 112 is the emergency number operating 24/7. The National Addiction Helpline “Uzależnienia” run by the National Center for Counteracting Addiction is free and open daily from 16 to 21 at 800 199 990. Number 800 100 100 serves parents and teachers, and 116 123 is a crisis helpline for adults.

Hospital treatment is symptomatic because there is no antidote for this group. Seizures and agitation are treated, blood pressure and heart rate controlled, kidney function monitored, and sedation provided in intensive care for severe cases. Identification requires liquid chromatography coupled with mass spectrometry, available in toxicology labs, not routine emergency diagnostics.

Therefore, packaging is often more valuable than witness accounts. It narrows search, speeds analysis, and protects against diagnostic errors when symptoms resemble other poisonings. Secure it in a sealed bag and hand it to rescue or police teams.

How to recognize these products in the environment?

Packaging is usually a small foil sachet with colorful graphics and a trade name like Spice, K2, Mocarz, or Mamba. The label states the product is not intended for consumption or is called “herbal blend.” Contents are crushed herbs with a chemical smell, different from hemp dried flower.

Signals from the user can be clearer than the product itself. Sudden episodes of extreme agitation or aggression, disorientation, seizures, loss of consciousness, and repeated emergency visits with acute mental disorder diagnosis do not fit the marijuana picture. Symptoms lasting several hours or days are also atypical.

Important diagnostically: standard immunochemical tests detect THC metabolites and will not detect these compounds. Literature reviews list evading routine tests as one reason for this group’s popularity. A negative home test result excludes nothing, and confirmation requires dedicated toxicological analysis.

If suspicion concerns a close person, do not start with confrontation. Secure found substance in a sealed bag with date, contact an addiction treatment clinic, and keep evidence for the doctor.

One thing complicates recognition more than all others combined. Because trade names and composition change every few months, no brand list stays current long. Last year’s packaging appearance tells little about today’s substances, and the same label can hide a completely different molecule than before.

The sales channel has also changed. Shops openly selling designer drugs disappeared from Polish cities, and trade moved to messengers and ads where no label can be seen. Prevention today relies more on behavior observation and conversation than spotting sachets.

How do CBD and CBG differ from synthetic cannabinoids?

They differ by category, not shade of the same category. Cannabidiol comes from industrial hemp, does not stimulate the CB1 receptor, and in cell studies weakens the receptor’s response to agonists (Laprairie 2015). Synthetics act exactly oppositely. They are pharmacological opposites, not variants of the same phenomenon.

The legal difference is equally sharp. Cannabidiol is not listed in any Polish controlled substance schedules, and industrial hemp products are legal if the sum of delta-9-THC and tetrahydrocannabinolic acid does not exceed 0.3% dry mass. This value has applied since May 7, 2022; previously it was 0.20%. Synthetic cannabinoids are banned without exception.

The third difference concerns known package content. Legal oil has a certificate of analysis for a specific batch, with cannabinoid content and testing for heavy metals, pesticides, and solvent residues. A designer drug sachet has none. Even lab analysis only shows what was in the tested sample, not the rest of the package.

Separately, HHC must be mentioned because it is often lumped with JWH series synthetics, which is a mistake both ways. HHC is a controlled substance in Poland and cannot be traded, but it does not belong to the group III-NPS described above and is not a full agonist like MDMB-CHMICA. Details of its status are described in a separate text about HHC and its legality in Poland.

Confusing these categories harms both sides and is not a word dispute. Calling legal oil a “designer drug” discourages a product with lab testing and known composition. Calling a Spice sachet a “herbal marijuana substitute” suggests similarity that does not exist pharmacologically or in risk. Name precision here is a safety element, not style.

Cannabigerol deserves a separate sentence because it is often lumped in the same drawer. It is another industrial hemp component, sold in the same forms as cannabidiol, and is not listed in controlled substance schedules. It shares nothing with JWH series synthetics except the word “cannabinoid” in the name.

What is synthetic THC and is it legal?

Under “synthetic THC” three different groups are hidden: delta-9-THC obtained in the lab, semi-synthetic THC-related compounds like HHC or THCP, and the synthetic cannabinoids described above. Delta-9-THC, its isomers, HHC, and THCP variants are listed by name in Polish controlled substance schedules, some only since 2025 and 2026 (Dz.U. 2026 pos. 934).

The list where a molecule is placed determines the provision, not legality. Possession of a psychotropic substance is subject to art. 62, and new psychoactive substances to art. 62b, as shown in the penalty table above. Details of semi-synthetics are collected in the HHC, HHC-O and THCP in Poland summary, and delta-8 and delta-10 isomers are described in the post Are delta-8 and delta-10 THC legal in Poland 2026.

Frequently Asked Questions

What are synthetic cannabinoids and how do they differ from THC?

These are laboratory-made compounds that bind to CB1 and CB2 receptors, applied onto inert herbs in solution form. THC only partially stimulates the CB1 receptor, while these compounds fully activate it. A literature review describes their action as 2 to 100 times stronger than THC in laboratory and animal studies (Castaneto 2014).

Are synthetic cannabinoids legal in Poland?

No. Named compounds, including JWH-018, AM-2201, and MDMB-CHMICA, are listed in the schedule of psychotropic substances group II-P, and HU-210 among narcotics group I-N. A separate list covers the entire group III-NPS by molecular structure description, so the ban also extends to unnamed derivatives.

Why are Spice and K2 more dangerous than marijuana?

Because they fully activate the CB1 receptor without the natural ceiling effect that THC has, and without cannabidiol, which in the plant weakens the receptor’s response. Additionally, the substance is unevenly distributed on the herb, so the dose is not consistent even within a single package.

What symptoms does synthetic cannabinoid poisoning cause?

In an observation of 44 emergency room patients, central nervous system depression occurred in 61%, disorientation in 45%, generalized seizures in 27%, and symptoms lasted a day or longer in 34% (Hermanns-Clausen 2018). Acute kidney failure, increased blood pressure, and respiratory disorders were also described.

Will a standard drug test detect a designer drug?

No. Immunochemical tests detect THC metabolites, not synthetic compounds, and this gap was one reason for the popularity of this group. Confirmation requires dedicated analysis in a toxicology laboratory. A negative home test result therefore excludes nothing.

What to do if synthetic drug poisoning is suspected?

Call 112 immediately and secure the packaging for toxicological examination. Place an unconscious person who is breathing in the recovery position and monitor breathing. Family counseling is provided by the National Addiction Helpline ‘Uzależnienia’ at 800 199 990, open daily from 16 to 21.

Are synthetic cannabinoids addictive?

Withdrawal syndrome descriptions exist but the evidence base is thin: a systematic review found eleven case reports (Sharma and Weinstein 2025). Psychosis, agitation, nausea, and seizures were most often noted, usually within one or two days after cessation. The authors assess this syndrome as poorly studied.

Is HHC the same as synthetics from the JWH group?

No. HHC is a controlled substance in Poland, so its trade is prohibited, but it is a different category than compounds from the JWH or AB-CHMINACA series. It does not belong to the structurally defined group III-NPS in the list and is not a full CB1 receptor agonist with the potency described for those molecules.

Summary

Synthetic cannabinoids and cannabis cannabinoids are two separate realities connected only by name and herb appearance. The first group consists of laboratory molecules, full CB1 receptor agonists, sprayed on herbs in unknown concentration, illegal in Poland in two independent ways. The second consists of plant components with a completely different action profile and legal status.

This editorial removed from the text all numbers that could not be found in an accessible study: the number of monitored compounds, annual death count in the EU, hospitalization percentages from poisoning databases, concentration multipliers in “hot spots”, and mortality reduction after quick intervention. Instead, data from specific clinical observations and a Polish fatal case description were included. Where evidence is lacking, it is stated plainly because in a topic with such stakes, softening would be worse than silence.

If you use industrial hemp products, choose those with a certificate of analysis for a specific batch and buy where this document is available before purchase. Unlabeled “herbs for smoking” from ads or messengers have no counterpart in legal trade and cannot be assessed before use.

In case of poisoning or suspected use, call 112. Addiction helpline: 800 199 990, daily 16-21. Parents and teachers helpline: 800 100 100. Crisis helpline for adults: 116 123.

Certified industrial hemp oils are available in the oils category at u Bucha store.

This article is informational and educational and does not constitute medical advice. Before starting cannabis or CBD for therapeutic purposes, consult a doctor, especially if you take other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-11 · Updated: 2026-09-23